GLP-1/glucagon receptor co-agonism for treatment of obesity
Open accessThe DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Abstract
Over a relatively short period, obesity and type 2 diabetes have come to represent a large medical and economic burden to global societies. The epidemic rise in the prevalence of obesity has metabolic consequences and is paralleled by an increased occurrence of other diseases, such as diabetes, cancer and cardiovascular complications. Together, obesity and type 2 diabetes constitute one of the more preventable causes of premature death and the identification of novel, safe and effective anti-obesity drugs is of utmost importance. Pharmacological attempts to treat obesity have had limited success, with notable adverse effects, rendering bariatric surgery as the only current therapy for substantially improving body weight. Novel unimolecular, multifunctional peptides have emerged as one of the most promising medicinal approaches to enhance metabolic efficacy and restore normal body weight. In this review, we will mainly focus on the discovery and translational relevance of dual agonists that pharmacologically function at the receptors for glucagon and glucagon-like peptide-1. Such peptides have advanced to clinical evaluation and inspired the pursuit of multiple related approaches to achieving polypharmacy within single molecules.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This is achieved by enhancing the metabolic rate through the stimulation of hepatic glucose production and activating thermogenic pathways in brown adipose tissue [31].”
From Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta‐Analysis of Randomised Controlled Trials (2026) · cites this paper as [31]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“They work primarily by increasing energy expenditure and promoting weight loss independently of GLP‐1‐mediated appetite suppression.”
From Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta‐Analysis of Randomised Controlled Trials (2026) · cites this paper as [31]
The cited source says what the claim attributes to it.
In the citing paper
“Combining both glucagon receptor and GLP-1 receptor agonism in a single molecule could target weight loss through multiple mechanisms of action to enhance the level of weight loss possible [18].”
In the citing paper
“Since the activation of these pathways sometimes produces opposite effects, the concurrent action on two or more of them could result in a complementary and synergistic effect [154].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [154]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Positional cloning of the mouse obese gene and its human homologue
Zhang, Y., Proenca, R., Maffei, M., Barone, M., Leopold, L., & Friedman, J. M. (1994) · Nature · doi:10.1038/372425a0 · Cited by 13,419
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“Similarly, recent long-term studies of liraglutide and semaglutide, focusing on cardiovascular outcomes in individuals with type 2 diabetes, reveal a similar incidence of pancreatitis between groups treated with the GLP-1R agonists and placebo [31, 41].”
BackgroundSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“Similarly, recent long-term studies of liraglutide and semaglutide, focusing on cardiovascular outcomes in individuals with type 2 diabetes, reveal a similar incidence of pancreatitis between groups treated with the GLP-1R agonists and placebo [31, 41].”
BackgroundGlobal estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642 · cited 1×
“5% of the global population) [4] and this number is expected to rise to 592 million by 2035 [5].”
BackgroundBiology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 3×
“cially in response to meals high in fat and carbohydrates [14].”
BackgroundInfluentialLixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 1×
“In this regard, clinical study of lixisenatide in individuals with type 2 diabetes and acute coronary syndrome did not reveal an association with pancreatitis [40].”
BackgroundChang, S.-H., Stoll, C. R. T., Song, J., Varela, J. E., Eagon, C. J., & Colditz, G. A. (2014) · JAMA Surgery · doi:10.1001/jamasurg.2013.3654 · Cited by 1,688
Medical Consequences of Obesity
Bray, G. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0535 · Cited by 1,538
Heymsfield, S. B., Greenberg, A. S., Fujioka, K., Dixon, R. M., Kushner, R., Hunt, T., Lubina, J. A., Patane, J., Self, B., Hunt, P., et al. (1999) · JAMA · doi:10.1001/jama.282.16.1568 · Cited by 1,422
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347 · cited 2×
“However, these therapies are commonly accompanied by adverse gastrointestinal and cardiovascular effects that limit their use [12].”
BackgroundGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“Lixisenatide is potent at the GLP-1R and has a half-life of 3–4 h [22].”
BackgroundDiscovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 2×
“Similar to liraglutide, semaglutide (Novo Nordisk) is a fatty-acylated GLP-1 analogue with a stearic-diacid at lysine position 20, linked via a di-aminoethoxy, γ-glutamic acid spacer, and an aminoisobutyric residue at position 2 to provide protection from DPP-IV degradation [28].”
BackgroundPancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Magkos, F., Fraterrigo, G., Yoshino, J., Luecking, C., Kirbach, K., Kelly, S. C., de las Fuentes, L., He, S., Okunade, A. L., Patterson, B. W., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.02.005 · Cited by 886 · cited 1×
“When sustained, this degree of weight loss can provide meaningful improvements in metabolism and lipid management [11].”
Background(1992) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/55.2.615s · Cited by 748
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · cited 10×
“Finally, in obese diabetic individuals, the GLP1R/GIPR/GcgR tri-agonist may be the most appropriate option, having the greatest potential to improve metabolism by weight-dependent and -independent mechanisms.”
BackgroundInfluentialSelf-citationA rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Finan, B., Yang, B., Ottaway, N., Smiley, D. L., Ma, T., Clemmensen, C., Chabenne, J., Zhang, L., Habegger, K. M., Fischer, K., et al. (2015) · Nature Medicine · doi:10.1038/nm.3761 · Cited by 645
Self-citationA new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Self-citationGelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563
Wild, D., von Maltzahn, R., Brohan, E., Christensen, T., Clauson, P., & Gonder-Frederick, L. (2007) · Patient Education and Counseling · doi:10.1016/j.pec.2007.05.003 · Cited by 545
Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
Sandoval, D. A., & D'Alessio, D. A. (2015) · Physiological Reviews · doi:10.1152/physrev.00013.2014 · Cited by 498 · cited 3×
“The appetitesuppressing effect of GLP-1 is mediated by its action in the brain, whereas its glucose-lowering effect is mainly attributed to enhancement of glucose-stimulated insulin secretion [74].”
BackgroundOxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans
Cohen, M. A., Ellis, S. M., Le Roux, C. W., Batterham, R. L., Park, A., Patterson, M., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030421 · Cited by 472
Lifetime Health and Economic Consequences of Obesity
Thompson, D., Edelsberg, J., Colditz, G. A., Bird, A. P., & Oster, G. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.18.2177 · Cited by 457
Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2390 · Cited by 435
Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., et al. (2009) · Diabetes · doi:10.2337/db09-0278 · Cited by 409
The metabolic actions of glucagon revisited
Habegger, K. M., Heppner, K. M., Geary, N., Bartness, T. J., DiMarchi, R., & Tschöp, M. H. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.187 · Cited by 406
Self-citationNeuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect
Sisley, S., Gutierrez-Aguilar, R., Scott, M., D’Alessio, D. A., Sandoval, D. A., & Seeley, R. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72434 · Cited by 397
Long-term weight loss maintenance in the United States
Kraschnewski, J. L., Boan, J., Esposito, J., Sherwood, N. E., Lehman, E. B., Kephart, D. K., & Sciamanna, C. N. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.94 · Cited by 381
Wynne, K., Park, A. J., Small, C. J., Meeran, K., Ghatei, M. A., Frost, G. S., & Bloom, S. R. (2006) · International Journal of Obesity · doi:10.1038/sj.ijo.0803344 · Cited by 363
Russell-Jones, D., Cuddihy, R. M., Hanefeld, M., Kumar, A., González, J. G., Chan, M., Wolka, A. M., Boardman, M. K., & on behalf of the DURATION-4 Study Group (2012) · Diabetes Care · doi:10.2337/dc11-1107 · Cited by 339
Targeted estrogen delivery reverses the metabolic syndrome
Finan, B., Yang, B., Ottaway, N., Stemmer, K., Müller, T. D., Yi, C.-X., Habegger, K., Schriever, S. C., García-Cáceres, C., Kabra, D. G., et al. (2012) · Nature Medicine · doi:10.1038/nm.3009 · Cited by 337
Self-citationMauvais-Jarvis, F. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2010.10.002 · Cited by 335 · cited 1×
“For example, it is known that oestrogen is an anorectic hormone that also promotes thermogenesis [94, 95].”
BackgroundGlucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice
Lee, Y., Wang, M.-Y., Du, X. Q., Charron, M. J., & Unger, R. H. (2011) · Diabetes · doi:10.2337/db10-0426 · Cited by 327 · cited 1×
“Furthermore, mice made diabetic by streptozotocin (STZ) administration, but genetically deficient for the GcgR, display normal glucose tolerance [49].”
BackgroundOxyntomodulin Inhibits Food Intake in the Rat
Dakin, C. L., Gunn, I., Small, C. J., Edwards, C. M. B., Hay, D. L., Smith, D. M., Ghatei, M. A., & Bloom, S. R. (2001) · Endocrinology · doi:10.1210/endo.142.10.8430 · Cited by 281
Hormonal regulation of hormone-sensitive lipase activity and mRNA levels in isolated rat adipocytes.
Slavin, B. G., Ong, J. M., & Kern, P. A. (1994) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41151-4 · Cited by 261
Tan, T. M., Field, B. C. T., McCullough, K. A., Troke, R. C., Chambers, E. S., Salem, V., Gonzalez Maffe, J., Baynes, K. C. R., De Silva, A., Viardot, A., et al. (2013) · Diabetes · doi:10.2337/db12-0797 · Cited by 258
Gier, B., Matveyenko, A. V., Kirakossian, D., Dawson, D., Dry, S. M., & Butler, P. C. (2012) · Diabetes · doi:10.2337/db11-1109 · Cited by 255
Rosenstock, J., Raccah, D., Korányi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013) · Diabetes Care · doi:10.2337/dc12-2709 · Cited by 253
Loonen, A. J. M., & Ivanova, S. A. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00394 · Cited by 247
Minireview: Glucagon in the Pathogenesis of Hypoglycemia and Hyperglycemia in Diabetes
Cryer, P. E. (2012) · Endocrinology · doi:10.1210/en.2011-1499 · Cited by 242
Henderson, S. J., Konkar, A., Hornigold, D. C., Trevaskis, J. L., Jackson, R., Fritsch Fredin, M., Jansson‐Löfmark, R., Naylor, J., Rossi, A., Bednarek, M. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12735 · Cited by 240
Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes
Rosenstock, J., Reusch, J., Bush, M., Yang, F., Stewart, M., & for the Albiglutide Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0366 · Cited by 237
Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
Tschöp, M. H., Finan, B., Clemmensen, C., Gelfanov, V., Perez-Tilve, D., Müller, T. D., & DiMarchi, R. D. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.021 · Cited by 235
Self-citationNauck, M. A., Petrie, J. R., Sesti, G., Mannucci, E., Courrèges, J.-P., Lindegaard, M. L., Jensen, C. B., & Atkin, S. L. (2016) · Diabetes Care · doi:10.2337/dc15-0165 · Cited by 233
Biologic actions and therapeutic potential of the proglucagon-derived peptides
Drucker, D. J. (2005) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0017 · Cited by 230
Maggard-Gibbons, M., Maglione, M., Livhits, M., Ewing, B., Maher, A. R., Hu, J., Li, Z., & Shekelle, P. G. (2013) · JAMA · doi:10.1001/jama.2013.4851 · Cited by 223
Sloop, K. W., Cao, J. X.-C., Siesky, A. M., Zhang, H. Y., Bodenmiller, D. M., Cox, A. L., Jacobs, S. J., Moyers, J. S., Owens, R. A., Showalter, A. D., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420911 · Cited by 219
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
Fonseca, V. A., Alvarado-Ruiz, R., Raccah, D., Boka, G., Miossec, P., Gerich, J. E., & on behalf of the EFC6018 GetGoal-Mono Study Investigators (2012) · Diabetes Care · doi:10.2337/dc11-1935 · Cited by 218
Kazda, C. M., Ding, Y., Kelly, R. P., Garhyan, P., Shi, C., Lim, C. N., Fu, H., Watson, D. E., Lewin, A. J., Landschulz, W. H., et al. (2016) · Diabetes Care · doi:10.2337/dc15-1643 · Cited by 212
Petersen, K. F., & Sullivan, J. T. (2001) · Diabetologia · doi:10.1007/s001250100006 · Cited by 209
Liang, Y., Osborne, M. C., Monia, B. P., Bhanot, S., Gaarde, W. A., Reed, C., She, P., Jetton, T. L., & Demarest, K. T. (2004) · Diabetes · doi:10.2337/diabetes.53.2.410 · Cited by 202
Finan, B., Clemmensen, C., Zhu, Z., Stemmer, K., Gauthier, K., Müller, L., De Angelis, M., Moreth, K., Neff, F., Perez-Tilve, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.014 · Cited by 191
Self-citationBiochemical and histological effects of exendin-4 (exenatide) on the rat pancreas
Nachnani, J. S., Bulchandani, D. G., Nookala, A., Herndon, B., Molteni, A., Pandya, P., Taylor, R., Quinn, T., Weide, L., & Alba, L. M. (2010) · Diabetologia · doi:10.1007/s00125-009-1515-4 · Cited by 189
Tiano, J. P., Delghingaro-Augusto, V., Le May, C., Liu, S., Kaw, M. K., Khuder, S. S., Latour, M. G., Bhatt, S. A., Korach, K. S., Najjar, S. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44564 · Cited by 180
Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
Salem, V., Izzi‐Engbeaya, C., Coello, C., Thomas, D. B., Chambers, E. S., Comninos, A. N., Buckley, A., Win, Z., Al‐Nahhas, A., Rabiner, E. A., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12585 · Cited by 167
Hyperglycemia of Diabetic Rats Decreased by a Glucagon Receptor Antagonist
Johnson, D. G., Goebel, C. U., Hruby, V. J., Bregman, M. D., & Trivedi, D. (1982) · Science · doi:10.1126/science.6278587 · Cited by 166
Glucagon is the key factor in the development of diabetes
Lee, Y. H., Wang, M.-Y., Yu, X.-X., & Unger, R. H. (2016) · Diabetologia · doi:10.1007/s00125-016-3965-9 · Cited by 166
Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake
Cegla, J., Troke, R. C., Jones, B., Tharakan, G., Kenkre, J., McCullough, K. A., Lim, C. T., Parvizi, N., Hussein, M., Chambers, E. S., et al. (2014) · Diabetes · doi:10.2337/db14-0242 · Cited by 159
Jendle, J., Grunberger, G., Blevins, T., Giorgino, F., Hietpas, R. T., & Botros, F. T. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2810 · Cited by 158
Dakin, C. L., Small, C. J., Park, A. J., Seth, A., Ghatei, M. A., & Bloom, S. R. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00233.2002 · Cited by 144
Nauck, M., Rizzo, M., Johnson, A., Bosch-Traberg, H., Madsen, J., & Cariou, B. (2016) · Diabetes Care · doi:10.2337/dc15-2479 · Cited by 143
Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency
NAIR, K. S. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-5-896 · Cited by 141
Hormonal control of substrate cycling in humans.
Miyoshi, H., Shulman, G. I., Peters, E. J., Wolfe, M. H., Elahi, D., & Wolfe, R. R. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113487 · Cited by 139
Clemmensen, C., Chabenne, J., Finan, B., Sullivan, L., Fischer, K., Küchler, D., Sehrer, L., Ograjsek, T., Hofmann, S. M., Schriever, S. C., et al. (2014) · Diabetes · doi:10.2337/db13-1609 · Cited by 136
Self-citationLorenz, M., Evers, A., & Wagner, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.022 · Cited by 127
GLP-1 based therapeutics: simultaneously combating T2DM and obesity
Heppner, K. M., & Pérez–Tilve, D. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00092 · Cited by 126
The future role of gut hormones in the treatment of obesity
Troke, R. C., Tan, T. M., & Bloom, S. R. (2014) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622313506730 · Cited by 125
The Human GLP-1 Analog Liraglutide and the Pancreas
Nyborg, N. C. B., Mølck, A.-M., Madsen, L. W., & Bjerre Knudsen, L. (2012) · Diabetes · doi:10.2337/db11-0936 · Cited by 125
Kelly, R. P., Garhyan, P., Raddad, E., Fu, H., Lim, C. N., Prince, M. J., Pinaire, J. A., Loh, M. T., & Deeg, M. A. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12446 · Cited by 110 · cited 1×
“Interestingly, recent clinical studies have confirmed the glucose-lowering effects of GcgR antagonism in individuals with type 2 diabetes [54, 55].”
BackgroundA Novel Glucagon Receptor Antagonist Inhibits Glucagon-Mediated Biological Effects
Qureshi, S. A., Rios Candelore, M., Xie, D., Yang, X., Tota, L. M., Ding, V. D.-H., Li, Z., Bansal, A., Miller, C., Cohen, S. M., et al. (2004) · Diabetes · doi:10.2337/diabetes.53.12.3267 · Cited by 109
Stimulation of Metabolism of Rat Brown Adipose Tissue by Addition of Lipolytic Hormones in Vitro
Joel, C. D. (1966) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)96838-9 · Cited by 102
KUROSHIMA, A., & YAHATA, T. (1979) · The Japanese Journal of Physiology · doi:10.2170/jjphysiol.29.683 · Cited by 100
Finan, B., Clemmensen, C., & Müller, T. D. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.07.003 · Cited by 88
Self-citationGlucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitus
TODD, J. F., WILDING, J. P. H., EDWARDS, C. M. B., KHAN, F. A., GHATEI, M. A., & BLOOM, S. R. (1997) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1997.1490691.x · Cited by 87
Ostawal, A., Mocevic, E., Kragh, N., & Xu, W. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0180-0 · Cited by 86
Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs
Druce, M. R., Minnion, J. S., Field, B. C. T., Patel, S. R., Shillito, J. C., Tilby, M., Beale, K. E. L., Murphy, K. G., Ghatei, M. A., & Bloom, S. R. (2009) · Endocrinology · doi:10.1210/en.2008-0828 · Cited by 84
Physiological Effect of Glucagon in Human Isolated Adipocytes
Perea, A., Clemente, F., Martinell, J., Villanueva-Peñacarrillo, M., & Valverde, I. (1995) · Hormone and Metabolic Research · doi:10.1055/s-2007-979981 · Cited by 84
Apovian, C. M., Garvey, W. T., & Ryan, D. H. (2015) · Obesity · doi:10.1002/oby.21140 · Cited by 72
The Effect of Glucagon on the Metabolic Rate of Rats
Davidson, I. W. F., Salter, J., & BEST, C. H. (1960) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/8.5.540 · Cited by 70
Physiology and pathophysiology of incretins in the kidney
von Websky, K., Reichetzeder, C., & Hocher, B. (2013) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000437542.77175.a0 · Cited by 68
DPP‐IV‐resistant, long‐acting oxyntomodulin derivatives
Santoprete, A., Capitò, E., Carrington, P. E., Pocai, A., Finotto, M., Langella, A., Ingallinella, P., Zytko, K., Bufali, S., Cianetti, S., et al. (2011) · Journal of Peptide Science · doi:10.1002/psc.1328 · Cited by 65
Optimization of the Native Glucagon Sequence for Medicinal Purposes
Chabenne, J. R., DiMarchi, M. A., Gelfanov, V. M., & DiMarchi, R. D. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400605 · Cited by 65
Self-citationModified metabolic responsiveness to glucagon in cold-acclimated and heat-acclimated rats
Doi, K., & KUROSHIMA, A. (1982) · Life Sciences · doi:10.1016/0024-3205(82)90614-2 · Cited by 63
Gotfredsen, C. F., Mølck, A.-M., Thorup, I., Nyborg, N. C. B., Salanti, Z., Knudsen, L. B., & Larsen, M. O. (2014) · Diabetes · doi:10.2337/db13-1087 · Cited by 60
Kerr, B. D., Flatt, P. R., & Gault, V. A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.08.010 · Cited by 56
Dulaglutide: The Newest GLP-1 Receptor Agonist for the Management of Type 2 Diabetes
Thompson, A. M., & Trujillo, J. M. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028014564180 · Cited by 51
Abraham, M. A., & Lam, T. K. T. (2016) · Diabetologia · doi:10.1007/s00125-016-3950-3 · Cited by 48
Schwenk, R. W., Baumeier, C., Finan, B., Kluth, O., Brauer, C., Joost, H.-G., DiMarchi, R. D., Tschöp, M. H., & Schürmann, A. (2015) · Diabetologia · doi:10.1007/s00125-014-3478-3 · Cited by 46
Self-citationBianchi, E., Carrington, P. E., Ingallinella, P., Finotto, M., Santoprete, A., Petrov, A., Eiermann, G. J., Kosinski, J. R., Marsh, D. J., Pocai, A., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.09.016 · Cited by 45
Kazierad, D. J., Bergman, A., Tan, B., Erion, D. M., Somayaji, V., Lee, D. S., & Rolph, T. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12672 · Cited by 44
Recent progress in the development of small-molecule glucagon receptor antagonists
Sammons, M. F., & Lee, E. C. Y. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.07.092 · Cited by 43
Synergistic interactions between Fenfluramine and Phentermine
Wellman, P. J., & Maher, T. J. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800920 · Cited by 43
Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes
Cornell, S. (2012) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2012.01342.x · Cited by 39
An Evidence-Based and Practical Approach to Using Bydureon™ in Patients With Type 2 Diabetes
Painter, N., Morello, C., Singh, R., & McBane, S. (2013) · Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2013.02.120174 · Cited by 32
Wang, Y., Du, J., Zou, H., Liu, Y., Zhang, Y., Gonzalez, J., Chao, E., Lu, L., Yang, P., Parker, H., et al. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201606321 · Cited by 23
KAZDA, C. M., Ding, Y., Kelly, R. P., Garhyan, P., Shi, C., Lim, C. N., Fu, H., Watson, D. E., Lewin, A. J., Landschulz, W. H., et al. (2016) · Diabetes Care · doi:10.2337/dci16-0030 · Cited by 10
Research works printed but not linked: 2
- Roglic G, World Health Organization (2016) Global report on diabetes. World Health Organization, Geneva
- Lao J, Hansen BC, Dimarchi R, Pocai A (2013) Effect of GLP1R/GCGR dual agonist in monkeys. Diabetes 62:A257–A257
Cited by
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
G protein-coupled receptors: structure- and function-based drug discovery
Yang, D., Zhou, Q., Labroska, V., Qin, S., Darbalaei, S., Wu, Y., Yuliantie, E., Xie, L., Tao, H., Cheng, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00435-w · Cited by 632
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Sanyal, A. J., Bedossa, P., Fraessdorf, M., Neff, G. W., Lawitz, E., Bugianesi, E., Anstee, Q. M., Hussain, S. A., Newsome, P. N., Ratziu, V., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2401755 · Cited by 528
Emerging Targets in Type 2 Diabetes and Diabetic Complications
Demir, S., Nawroth, P. P., Herzig, S., & Ekim Üstünel, B. (2021) · Advanced Science · doi:10.1002/advs.202100275 · Cited by 525
Metadata
- Authors
- Sánchez-Garrido, M. A., Brandt, S. J., Clemmensen, C., Müller, T. D., DiMarchi, R. D., & Tschöp, M. H.
- Affiliations
- Helmholtz Munich (DE)
- Indiana University Bloomington (US)
- Corresponding author
- DiMarchi, Richard D.
- Tschöp, Matthias H.
- Venue
- Diabetologia
- Published
- 2017-07-21
- Volume
- 60
- Issue
- 10
- Pages
- 1851-1861
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC6448809
- OpenAlex
- W2737611067
- Cited by
- 175
- References
- 97
- Citations by year
- 2026: 19 · 2025: 15 · 2024: 13 · 2023: 22 · 2022: 15 · 2021: 23 · 2020: 17 · 2019: 25 · 2018: 23 · 2017: 2
- FWCI
- 2.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Site cant be reached (submittedVersion, other-oa)
- Funders
- Alexander von Humboldt-Stiftung
- Lundbeckfonden (R210-2015-4001)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor, glucagon receptor, dual agonist, obesity, type 2 diabetes, anti-obesity drugs, peptide therapeutics, polypharmacy, bariatric surgery, weight loss
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Humans, Obesity, Receptors, Glucagon, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.